[go: up one dir, main page]

SE0302192D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0302192D0
SE0302192D0 SE0302192A SE0302192A SE0302192D0 SE 0302192 D0 SE0302192 D0 SE 0302192D0 SE 0302192 A SE0302192 A SE 0302192A SE 0302192 A SE0302192 A SE 0302192A SE 0302192 D0 SE0302192 D0 SE 0302192D0
Authority
SE
Sweden
Prior art keywords
novel compounds
solvate
meanings
pro
therapy
Prior art date
Application number
SE0302192A
Other languages
English (en)
Swedish (sv)
Inventor
David Cladingboel
Rhonan Ford
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302192A priority Critical patent/SE0302192D0/xx
Publication of SE0302192D0 publication Critical patent/SE0302192D0/xx
Priority to EP04749189A priority patent/EP1654217A1/en
Priority to US10/567,711 priority patent/US20070037830A1/en
Priority to PCT/SE2004/001154 priority patent/WO2005014529A1/en
Priority to JP2006522527A priority patent/JP2007501782A/ja

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/26Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0302192A 2003-08-08 2003-08-08 Novel compounds SE0302192D0 (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0302192A SE0302192D0 (sv) 2003-08-08 2003-08-08 Novel compounds
EP04749189A EP1654217A1 (en) 2003-08-08 2004-07-28 2- adamantyl derivatives as p2x7 receptor antagonists.
US10/567,711 US20070037830A1 (en) 2003-08-08 2004-07-28 2-Adamantyl derivatives as p2X7 receptor antagonists.
PCT/SE2004/001154 WO2005014529A1 (en) 2003-08-08 2004-07-28 2- adamantyl derivatives as p2x7 receptor antagonists.
JP2006522527A JP2007501782A (ja) 2003-08-08 2004-07-28 P2x7受容体アンタゴニストとしての2−アダマンチル誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302192A SE0302192D0 (sv) 2003-08-08 2003-08-08 Novel compounds

Publications (1)

Publication Number Publication Date
SE0302192D0 true SE0302192D0 (sv) 2003-08-08

Family

ID=27800872

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302192A SE0302192D0 (sv) 2003-08-08 2003-08-08 Novel compounds

Country Status (5)

Country Link
US (1) US20070037830A1 (xx)
EP (1) EP1654217A1 (xx)
JP (1) JP2007501782A (xx)
SE (1) SE0302192D0 (xx)
WO (1) WO2005014529A1 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
JP2007501270A (ja) * 2003-05-29 2007-01-25 アストラゼネカ・アクチエボラーグ P2X7受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
KR20090094336A (ko) 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 헤테로아릴 아미드 유도체
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
CA2682925A1 (en) 2007-04-10 2008-10-16 David C. Ihle Heteroaryl amide analogues
AU2008275891B2 (en) * 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
WO2009023623A1 (en) * 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
EP2105164B1 (en) 2008-03-25 2011-01-12 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
ATE541832T1 (de) 2009-04-14 2012-02-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2931717B1 (en) 2012-12-12 2016-12-07 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
CA2891499C (en) 2012-12-18 2021-07-06 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물
IL277602B2 (en) * 2018-03-29 2024-06-01 Centre Nat Rech Scient P2RX7 modulators in therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
KR20000065219A (ko) * 1996-05-20 2000-11-06 마르크 젠너 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드
EP1037878A2 (en) * 1997-11-21 2000-09-27 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
TR200102911T2 (tr) * 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
PT1406628E (pt) * 2001-07-02 2006-06-30 Akzo Nobel Nv Derivados de tera-hidroquinolina
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
JP2007501270A (ja) * 2003-05-29 2007-01-25 アストラゼネカ・アクチエボラーグ P2X7受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
WO2005014529A1 (en) 2005-02-17
EP1654217A1 (en) 2006-05-10
US20070037830A1 (en) 2007-02-15
JP2007501782A (ja) 2007-02-01

Similar Documents

Publication Publication Date Title
SE0302192D0 (sv) Novel compounds
TW200613243A (en) Novel compounds
DE602004024375D1 (de) Carboxamidderivate
SE0302811D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
SE0202539D0 (sv) Compounds
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
SE0104140D0 (sv) Novel Compounds
SE0301700D0 (sv) Novel compounds
MXPA05009985A (es) Ligandos de receptores de canabinoides.
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
ATE316083T1 (de) Adamantanderivate
IS6658A (is) Ný efnasambönd
TW200610527A (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
TW200800999A (en) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
IS6520A (is) Ný efnasambönd
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
SE0400284D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
GB0415365D0 (en) Pyrimidine derivatives
SE0401762D0 (sv) Novel compounds
ATE386725T1 (de) Heterocyclylverbindungen
TW200604197A (en) New compounds
SE0402925D0 (sv) Novel Compounds